# ConcertAI

> ConcertAI is a Cambridge, Massachusetts company that combines real-world clinical, genomic, imaging, and claims data with applied AI to accelerate cancer research and clinical development. Through its CARA AI platform, large independent oncology data network, and Digital Trial Solutions, it helps biopharma companies, healthcare providers, and medical societies design smarter trials, match patients faster, and generate evidence on how treatments perform outside controlled studies.

- **Founded:** 2017
- **Headquarters:** Cambridge, Massachusetts, United States
- **Founders:** Jeff Elton (Founding CEO, now Vice Chairman)
- **Team size:** ~1,300 employees
- **Products:** CARA AI, Real-World Data (RWD) Platform, Digital Trial Solutions (DTS), TeraRecon, CancerLinQ
- **Notable:** Reached an approximately $1.9B valuation with its 2022 Series C., Raised $300M total across Series B and C rounds., Built one of the largest independent oncology RWD networks (clinical, molecular, claims, imaging).

## Products & services

- **CARA AI** — A multi-modal data management, predictive AI, and generative AI platform that powers ConcertAI's clinical and research products.
- **Real-World Data (RWD) Platform** — One of the largest independent oncology data networks, combining clinical, molecular/genomic, medical claims, and imaging data for research and regulatory-grade analyses.
- **Digital Trial Solutions (DTS)** — A SaaS suite including Clinical Trial Optimization, patient-to-trial matching, and eCRF automation to speed enrollment and reduce trial burden for sponsors and sites.
- **TeraRecon** — Cloud-based, AI-enhanced medical imaging (radiology, oncology, cardiology, neurology, vascular) serving roughly 1,300 clinical sites, integrated into ConcertAI's research network.
- **CancerLinQ** — Oncology learning and research network acquired from ASCO, expanding ConcertAI's clinical data reach across community and academic practices.

## Achievements

- Reached an approximately $1.9B valuation with its 2022 Series C.
- Raised $300M total across Series B and C rounds.
- Built one of the largest independent oncology RWD networks (clinical, molecular, claims, imaging).
- Acquired CancerLinQ from ASCO to expand its oncology research network.
- Reported AI that tripled the efficiency of matching patients to cancer trials.
- Recognized among Fast Company's Most Innovative Companies.

## Latest updates

- **2025-05** — Eron Kelly appointed CEO; founder Jeff Elton transitioned to Vice Chairman to accelerate AI innovation and growth.
- **2024-06** — Introduced new AI solutions powered by real-world data at ASCO 2024.
- **2024-01** — Announced NeoGenomics collaboration on population-scale hematology RWD and generative AI; expanded BMS digital trials partnership at J.P. Morgan Healthcare Conference.
- **2023-12** — Announced agreement to acquire CancerLinQ from ASCO to build a leading oncology learning and research network.
- **2022-03** — Closed $150M Series C led by Sixth Street at a ~$1.9B valuation.

## Links

- Website: https://concertai.com
- LinkedIn: https://www.linkedin.com/company/concertai
- Twitter/X: https://twitter.com/ConcertAI
- YouTube: https://www.youtube.com/@ConcertAI

---

Profile page: https://yespress.io/concertai
Published by YesPress — https://yespress.io
Last updated: 2026-06-15